Problems with Profitability Beyond Borders

D&MD Focus Report

Published: December, 2001

D&MD's latest Focus Report is a compilation of some of the best recent articles from D&MD Newsletter, intended to inform you of the current motivations and opportunities within drug discovery.

While it should come as no surprise that the breadth and depth of biomedical advances are not due solely to the efforts of US researchers and manufacturers, it may be shocking to some to learn just how differently these functions take place overseas. This is true even in Europe, where the health requirements of the public demand different approaches-and create different marketing niches-than those utilized in the US.

In D&MD's latest Focus Report-International Issues in Biotechnology & Pharmaceuticals: Problems and Profitability Beyond Borders-D&MD Newsletter's most experienced international pharmaceutical and biotechnology analysts collaborate to describe the major events that have driven progress in drug discovery technology and marketing. They closely examine the successes and failures that have been experienced to date by corporations, institutions, and governments, and profile several of the key players and innovators in the international scene.

Learn About These Fundamental International Issues:

Contract research organizations

Reaction to stem cell research in Europe

Governmental approaches to generics in Spain, France, and Italy

European approaches to phytotherapy

Russian pharmaceutical industry in crisis

Innovative research collaborations in Scotland and Ireland

Plus, Discover the Novel Approaches to Pharmaceuticals and Biotechnology Taken By:

A2 Corp.

Elan Corp.

Genesis Research and Development

GPC Biotech

MorphoSys

Rhein Biotech

Serono

Shire Pharmaceuticals Group

Authors: G. Thor, Ph.D., J. Terryberry, B.S., J. Volland, M.D.

Publication date: Dectember 2001

Number of pages: 1000+ Pages, 130+ Exhibits, 35 Companies Profiled, Listing of Over 800 Web Sites

The baby boom generation, currently the largest demographic block in the world, is aging. The advances in medicine that have prolonged life expectancy, coupled with the large number of people approaching old age, suggests that there will be a major surge in geriatric neurologic diseases-this is already being observed.

Diseases of the nervous system are rapidly succumbing to molecular and genetic analysis. The human genome project along with the sciences of genomics, proteomics, and bioinformatics are providing breakthroughs in understanding diseases of the brain. The health and commercial benefits are now within reach.

D&MD's Neurological & Psychiatric Diseases: Pharamcological Treatments and Commercial Outlook in an Aging Population Report details the current arsenal of pharmaceutical treatments available for adult and geriatric neurological and psychiatric diseases. Emphasis is given to recently approved drug therapies and clinical trials with novel agents. Also discussed are pertinent controversies and issues highly relevant to the successful diagnosis and prognosis of brain disorders. Thus, the overview should prove invaluable to the development of newer, more effective compounds to treat dementia, movement disorders, neuropathy, depression, and other clinical nosologies. The Report will also provide researchers and pharmacologists guidance in regulating their research protocols and in obtaining funding.

Experts in their respective fields including biochemistry, molecular genetics, neuropathology, and clinical diagnosis have authored this report. Clinical data, cutting-edge research, current trends in ongoing projects in major pharmaceutical, and biotechnology research of the most common diseases affecting the aging nervous system are provided.

This Report helps the reader discover many pharmaceutical, neurologic, and psychiatric-oriented Web sites, including governmental, educational, commercial, journals/periodicals, clinical databases, and intstitutes. These sites are essential for remaining informed of current statuses and obtaining information in this fast-paced environment.

Neurological & Psychiatric Diseases: Pharamcological Treatments and Commercial Outlook in an Aging Population is aimed at both corporate and research professionals with a balanced attention to the clinical and commercial aspects of geriatric neurologic and psychiatric diseases.

Unique Benefits of this Report:

> Overview of the nervous system and the specific diseases affecting the aging population, analyzing the current market landscape.

> Presentation of clinical data and cutting-edge research in the field, providing insight into the means for the key players' success.

> Identification of key market trends in examining the diseases affecting the aging nervous system, helping the reader decide how to proceed in this industry.

> Discussion of the controversial issues involved in the diagnosis and prognosis of brain disorders, outlining the potential pitfalls.

> In-depth profiles of the leading companies involved in neurological and psychiatric diseases, identifying chief positions and strategy insights.

> Listing of current relevant references from journals and the Web throughout the report, providing a useful means of keeping updated in this ever-changing field.

Available in two formats: CD-ROM or PRINTED

Price: $4,950.00

Please contact me to discuss this report

CD-ROM Format Printed Format CD+Printed Format

Authors: By Pamela Bassett, D.M.D., M.B.A. and Lorraine Hochstuhl, M.B.A..

Publication date: January 2002

Number of pages: 380+ Pages, 79 Exhibits, 31 Companies Profiled

Cancer Therapeutics, Enabled by Drug Delivery Systems, will Quadruple by 2010

Each year, cancer is responsible for nearly 500,000 deaths in the U.S., making it the second leading cause of death in the nation. Further, conventional anticancer drugs are inherently toxic, exposing both the patient and the healthcare provider to risks. Drug delivery systems can be used to improve the solubility and stability of drug solutions to eliminate mixing and minimize exposure risks.

D&MD's Drug Delivery Systems in Cancer Therapeutics provides a detailed analysis of the significant role drug delivery systems will play in the anticancer market.

Unique Benefits of this Report Include:

> Detailed discussions on how drug delivery systems will shape the future of cancer therapy, highlighting lucrative market opportunities.

> Comprehensive overview of the challenges and advantages posed by different routes of administration, helping to determine the most effective choices.

> Extensive coverage of multiple drug delivery systems explaining the characteristics and benefits of each, keeping you up-to-date on the latest technologies.

> Thorough analysis of emerging trends within cancer therapeutics, identifying key market segments most effected by these trends.

> Useful tips for minimizing commercialization risks and maximizing sales, ensuring a successful product launch.

> In-depth company profiles of market-leaders developing the next wave in cancer therapy, helping you stay informed.

> The anticancer market is shifting. Get the latest industry analysis on the sector's future before it's in the past. Order today!

In-depth Company Profiles

Alza

Antigenics

Atrix Laboratories

Biovector Therapeutics

CellGate

Cell Gensys

ConjuChem

Diatos

Endocyte Pharmaceuticals

Enzon

Epic Therapeutics

Ethypharm SA

Eurand International

Genetronics Biomedical

Guilford Pharmaceuticals

Hydro Med Sciences

Inex Pharmaceutical Corp.

MediGene

Onyx Pharmaceuticals

Oxford Biomedica

Protarga

RTP Pharma

SkyePharma

SuperGen

Supratek

Targeted Genetics

Targeted Molecules

Valentis

Vical

Vion Pharmaceuticals

Zycos

Available in two formats: CD-ROM or PRINTED

Price: $4,950.00

Please contact me to discuss this report

CD-ROM Format Printed Format CD+Printed Format

Authors: By Pamela Bassett, D.M.D., M.B.A. and Lorraine Hochstuhl, M.B.A..

Publication date: January 2002

Number of pages: 313 Pages, 63 Exhibits, 21 Companies Profiled

Drug delivery technologies will be the enabling component of many of the future cardiovascular therapies.

Cardiovasculars were among the first drugs to benefit from the application of drug delivery systems. Since 1982, when transdermal formulations of nitrates were introduced, drug delivery systems have been used to improve cardiovascular drugs. In the next decade, drug delivery technologies will enable a spectrum of new therapies. Many of the newer biological-based treatments will require the use of these drug delivery technologies to deliver a protein, peptide, or gene to a specific location and provide a long-term availability of the therapeutic at that site over time. Ultimately, drug delivery technologies will be the enabling component of many of the future cardiovascular therapies.

With cardiovascular disease continuing to escalate worldwide, there is clearly an urgent need to expand the use of drug delivery technologies within this segment. The benefits will be tremendous - combining pharmaceuticals with devices to develop new life-saving approaches.

D&MD's Drug Delivery Systems In Cardiovascular Therapeutics Market Analysis Report divulges the great market potential of this industry through a detailed analysis of the significant role drug delivery systems will play in this market. In addition, this unique publication features company profiles detailing drug delivery technologies, cardiovascular drug pipelines, and alliances of key players in this space.

In-Depth Company Profiles

Angiotech Pharmaceuticals

Ark Therapeutics

AVI Biopharma

Cardion AG

CellGate

Collateral Therapeutics

ConjuChem

Curis

Emisphere Technologies

Endovasc, Ltd

Genetronics Biomedical, Ltd

Human Genome Sciences

MediGene

Oxford Biomedica Plc

Repair

SkyePharma

SuperGen

Targeted Genetics

Targeted Molecules

Valentis

Vical

Available in two formats: CD-ROM or PRINTED

Price: $4,950.00

Please contact me to discuss this report

CD-ROM Format Printed Format CD+Printed Format

Authors: by Pamela Bassett, D.M.D., M.B.A

Publication date: May 2001

Number of pages: 800+ Pages - 60+ Company Profiles - 50+ Exhibits

New technologies in the vaccine market will heighten competition and spur additional opportunities and growth.

Historically, vaccines have been treated as commodity products - now the advent of new technologies and the potential for patented technologies and products has infused life into the business - along with new profit potential due to improved pricing possibilities and higher margins. With well over 1,000 vaccines in research and development worldwide for infectious diseases, cancer, and other diseases, vaccines have become the fastest growing segment of the pharmaceutical industry. D&MD's thoroughly revised and updated version of its best-selling 1998 report, Vaccines: Emerging Technologies, Trends, and Market Opportunities, will inform you of the latest developments in vaccine technologies and how they will continue to play a critical role in the successful formulation of vaccines.

Unique Benefits of this Report:

Examination of the underpinnings of the fastest growing segment in the pharmaceutical industry, outlining key trends in the vaccines market

Analysis of the leading technologies and delivery systems driving emerging opportunities in vaccine development, putting you a step ahead of competitors

Comprehensive analysis of infectious disease and cancer market segments, identifying where the greatest opportunities lie

In-depth profiles of leading biopharmaceutical companies developing and delivering vaccines, highlighting industry leaders and strategy insights

Evaluation of the impact of vaccine strategic alliances, mergers, and acquisitions restructuring the market, recognizing the impact of the key collaborations

Discussion of the many issues that may prevent effective safety, reimbursement, distribution, and utilization of vaccines, informing you of possible obstacles to overcome

Without the development and use of new vaccines and continued emphasis on global prevention using existing vaccines, more and more of the population is at risk of contracting new diseases and diseases that were previously under control. The changing environment and increased travel between industrialized nations and developing countries will continuously enable the rapid spread, sharing of, and resultant mutation of microbial genetic information. How to ensure the future of those microbes with the potential consequence of both the resurgence of old infections and the rise of new outbreaks is hitherto unknown. Get the answers needed for success - order your copy of D&MD's Vaccines Report today!

» How are pharmaceutical industry trends driving growth in the vaccine segment?

» What are the environmental issues that will impact the vaccine market?

» How is the business model of successful vaccine companies evolving to ensure profitability?

» What is the potential for profit in the vaccine market?

» Which companies are positioned to take advantage of near-term growth opportunities?

» What role will the government play in structuring the market, and how can changes in government outlook alter the business structure to potentiate growth?

» Which segments of the market will support the fastest growth?

Available in two formats: CD-ROM or PRINTED

Price: $4,950.00

Please contact me to discuss this report

CD-ROM Format Printed Format CD+Printed Format

Authors: by Mind to Market Solutions Inc.

Publication date: Feb 2002

Number of pages: 250+ Pages, 90+ Exhibits, 3 Case Studies, 24 Company Profiles

Providing a window into the world of Canadian biotechnology-revealing the many opportunities for US and European companies to enhance market value.

Canada's biotech industry is full of opportunities‹with 89% of all Canadian biotech companies classified as small to mid-sized, there is a considerable need to seek out alliances with larger companies that are capable of supplying the missing pieces of the development puzzle. These needs open the door for large US and European companies to expand and fill their pipelines with products in late phase clinical development.

D&MD's Canadian Biotech Briefing looks at the primary areas of research and clinical focus of Canada's biotech companies, specifically publicly listed companies and their product pipelines and stage of clinical development, as well as the ways in which they raise capital and how they are valued compared to US companies.

This Briefing presents an inside look into the undervalued Canadian biotech scene. Learn about:

» The many hurdles that small and mid-sized Canadian companies need to overcome in order to get their products to market.

» The large number of unpartnered companies in Canada that require assistance with the development of their products that are in Phases II and III of clinical development.

» The great opportunities and considerable possibilities for larger companies to expand and fill their pipelines with products that are in Phases II and III of clinical development.

Available in two formats: CD-ROM or PRINTED

Price: $1,995.00

Please contact me to discuss this report

CD-ROM Format Printed Format CD+Printed Format

Author:>! !By Pamela Bassett, D.M.D., M.B.A. !!<Publication date: Dectember 2001

Number of pages: 500+ pages, 80+ Exhibits, 30+ Company Profiles

The total market for the regeneration and repair of tissues and organs is estimated to be $25 billion worldwide.

Each year, 40 to 90 million hospital days are attributed to the treatment of tissue and organ failure in the United States-accounting for approximately one half of the total annual expenditure on healthcare. An excess of $400 billion per year is estimated as the total national health care cost for the 8 million or so procedures performed on patients suffering end-stage organ failure or tissue loss within the US. With a continually aging population, these figures are certain to increase.

For these reasons, it is no wonder that the demand for improved diagnostics, therapeutics, and treatments of tissue and organ failure is so great. Ultimately, the use of tissue engineered systems will replace the present costly and timely methods of organ donor transplantations, surgical reconstruction, and other mechanical approaches with the regeneration and repair of tissues and organs. The benefits will spread to patients, the healthcare industry, and the biotechnology/biopharmaceutical industry alike.

In keeping up with the great market potential of this industry, D&MD offers the fully revised and updated third edition Market Analysis Report of the previous two best-sellers, Tissue Engineering: Technologies, Markets, and Opportunities.

Unique Benefits of This Report Include:

> Examination of tissue engineering market drivers, recognizing those players responsible for accelerating the maturation of emerging opportunities.

> Overview of the current logic and approaches within the tissue engineering field, highlighting the many appealing business opportunities.

> Review of the regulatory issues involved in developing tissue engineered products, helping to avoid setbacks or citations resulting from non-compliance.

> Assessment of the fundamental development of normal physiology and pathological processes, identifying what may result in the need to replace specific tissues.

> Evaluation of the structures, functions, and applications of various technologies within tissue engineering, identifying the strategic challenges inherent in the future of product development.

> Analysis of market strategies and product positioning, capitalizing on the bright outlook for the tissue engineering industry.

> Discussion of the market impact of tissue engineering technologies on the healthcare industry, solidifying the direct correlation between these industries.

> Examination of the key tissue engineering companies, including their products in development, technologies, and alliances, keeping you informed of who is doing what-and why.

Available in two formats: CD-ROM or PRINTED

Price: $4,950.00

Please contact me to discuss this report

CD-ROM Format Printed Format CD+Printed Format

Publication date: September 2001

Number of pages: 300 pages, 70 exhibits

Proteomic technologies offer significant opportunities to improve the drug discovery process. By focusing on protein activity levels, expression levels, and interactions, researchers are able to learn more about the role proteins play in causing and treating disease. Proteomics also aids in deciphering the mechanisms of disease and increasing both the opportunity to develop drugs with reduced side effects and an increased probability of clinical trial success. Proteomics has the potential to substantially increase the number of drug targets and thereby the number of new drugs. Proteomics is currently the focus of attention in biotech and pharma.

The drive to understand basic biological mechanisms has led to two distinct, yet related, approaches in the study of molecular biology: genomics and proteomics. Genomics is the study and identification of an organism's genetic makeup. Proteomics is the study of protein expression and protein interaction within cells. D&MD's Proteomics Report closely analyzes these emerging technologies, trends, and market opportunities, with emphasis on emerging technologies in start-up companies.

While some labs are automating the mass spectrometry and database searching portions of proteome analysis, the bottleneck continues to lie with the steps upstream: excising gel spots one by one, performing digests, and sample clean-up. There is a need to develop an approach that is easily automated and that will serve for the long term-an approach that will go beyond the most intensely stained spots on a 2-D gel to the spots that cannot be visualized using protein staining techniques, and which will not only identify the proteins, but characterize the structures by identifying changes in post translational modifications. For its full impact, proteomics needs to be performed in vivo.

D&MD's Proteomics Market Analysis Report is the sequel to its best-selling 1999 report, Proteomics: An Overview and Analysis of Current and Emerging Technologies, Competitive Landscape, and the Market Environment. With the recent developments in the field of proteomics, this Report will provide you with the critical information needed to evaluate technologies and remain competitive in order to become a leader in the proteomics space. This Report will:

Assist start-ups in identifying their competitors

Provide information for biotech companies for partnering purposes

Help pharma companies seeking acquisitions

Unique Benefits of this Report

» In-depth analysis of the technologies at the forefront of proteomics research at the pharmaceutical and biotechnology companies, outlining how these technologies are applied

» Presentation of exhibits that address some of the emerging technology platforms, elucidating the potential areas that could gain traction in this market

» Analysis of the partnerships and alliances the various proteomics players have forged, together with tables describing financings of these market participants, giving insight into potential market collaborations

» Special focus on the entrepreneurial entities in proteomics, showing how the start-ups are making an impact

» Examination of start-up proteomics players, in the US and Europe, that seek to dominate this emerging market opportunity to identify lead positions and potential future growth areas

» Comprehensive profiles of emerging commercial entities in proteomics, together with details of their respective technology platforms, identifying lead positions and strategy insights

Available in two formats: CD-ROM or PRINTED

Price: $4,950.00

Please contact me to discuss this report

CD-ROM Format Printed Format CD+Printed Format

Publication date: August 2001

Number of pages: 600+ Pages, 125+ Exhibits, 280+ Global Alliances, 30 Companies Profiled

After a significant respite during the '80s and most of the '90s, the antibody field has made a comeback. Antibodies are finding applications as therapeutics, as drug delivery vehicles, in diagnostics and imaging, and in drug discovery research for both screening and validation of targets. Among 113 currently approved biotech products currently in the market, monoclonal antibodies form an extremely exciting and emerging business area, with 10 therapeutic antibodies and 5 diagnostic products in the market. Additionally, there are about 75 antibodies currently in clinical trials, constituting nearly 20% of all biotech drugs in development.

Several factors have contributed to the current enthusiasm in the antibody drug market. First, the humanization of antibodies has increased the potential of efficacious antibody therapy and the elimination of HAMA response. Second, various in vitro technologies, specifically phage display systems, have provided avenues to generate efficiently large panels of human antibodies with relative ease. Third, human genome sequencing and related data-mining information are facilitating a generation of increasing numbers of drug targets (that are being leveraged by the antibody generation companies) for drug discovery and target validation, as well as for generating antibody therapeutic and diagnostic products.

D&MD's Market Analysis Report, Antibody Engineering: Technologies, Applications, and Business Opportunities, examines the genesis and progress of antibody engineering technologies, provides an in-depth review of the applications in therapeutic and diagnostic areas, and puts forward a comprehensive analysis of strategic licensing activities and commercial opportunities surrounding the antibody marketplace. Additionally, the Report provides information about the current industry players, as well as considers the strategic issues relating to the impact of monoclonal antibodies as renaissance products on the biopharmaceutical industry.

Unique Benefits of This Report:

Comprehensive summary of the history of recombinant antibody innovations, identifying the circumstances that led to today's industry

Review of the key antibody technologies, including genomics and proteomics-based high-throughput systems, presenting their many attributes and impact on drug discovery

Extensive coverage of the applications of antibody engineering and monoclonal antibody products in diagnostic and therapeutic areas, detailing the widespread significance of antibodies

Detailed discussion of the antibody industry, featuring thorough analyses, trends, and outlooks in the dealings of over 280 global alliances

In-depth company profiles of 30 pertinent companies, presenting the technologies, product pipelines, clinical development status, intellectual property estate, alliances, business outlook, and strategies of each

Analysis of overall industry trends, current and future products, existing revenues and forecasts, and business prospects and competition, highlighting where the industry is going and potential areas of opportunity.

Available in twoformats: CD-ROM or PRINTED

Price: $4,950.00

Please contact me to discuss this report

CD-ROM Format Printed Format CD+Printed Format

Publication date: October 2001

Number of pages: 500+ Pages, 80+ Exhibits, 320+ Global Alliances, 100+ Clinical Trials, 30 Companies Profiled

While only 10 monoclonals have been approved so far, there are more than 100 antibodies in clinical trials and hundreds more in preclinical development. A conservative estimate points to about 1,100 biotherapeutic products currently in preclinical studies. Present activities in the genomics area and the efforts in proteomics research, including antibodies, have increased the possibility of discovering many proteins with desirable therapeutic functions. As a result, the U.S. biotherapeutics market is expected to grow from the current $16 billion to $86 billion by 2025.

A glut of biotherapeutics, especially so many antibodies coming through the pipeline, is causing a bottleneck in production that may take years to open. While several companies have resorted to establishing larger production capabilities to cope with their individual production needs, others are optioning to utilize contract manufacturing organizations (CMOs) to satisfy the needs of production, rather than taking the risk of establishing their own manufacturing facilities. This has created a good opportunity and market niche for the CMOs. Indeed, the Contract Research Industry has experienced growth of 25% to 30% annually since 1995, and the overall value of the industry grew from $1.5 billion in 1995 to $4.5 billion in 1999.

D&MD's Market Analysis Report, Antibody Therapeutics: Production, Clinical Trials, and Strategic Issues, provides an in-depth examination of the status, upheavals, and challenges in the manufacturing arena of antibodies, in particular, and the biotherapeutics market place in general.

As interest in the antibody field grows in both the biotechnology and pharma sectors, primarily due to their versatility as therapeutics, diagnostics, and as reagents in drug discovery research, so grows the legal rambling about intellectual property (IP) situations. While controversy regarding IP position is nothing new to the antibody field, the court rulings of these patent skirmishes will have far-reaching monetary and product development repercussions for those companies involved in the lawsuits that also have major alliances with first-tier pharma companies.

D&MD's Antibody Therapeutics Report will benefit those individuals involved in the production, process development, analyticals, and formulations of the antibody therapeutics market. The Report will also prove beneficial for those seeking to learn more about the global trends in biopharma, including partnerships and alliances, intellectual property status, and court battles within the antibody industry.

Unique Benefits of this Report:

Overview of the methods and cutting-edge technologies utilized for the production of therapeutic antibodies, highlighting the benefits and shortcomings of such production systems.

Extensive coverage of the process development issues pertaining to the industrial scale production of antibodies, especially those of separation, purification, characterization, and carbohydrate attachment, detailing their impact on chemical and bioengineering processes.

Comprehensive summary of the manufacturing issues, current bottleneck in production, FDA's role, and status of capital investment, providing potential solutions to ease the holdup.

Detailed discussion of the clinical trial status of antibodies in various therapeutic areas, and overview of over 320 global alliances, outlining potential partnering options.

Review of the intellectual property situation and the status of litigations involving antibody patents, presenting their potential impact on the industry.

In-depth profiles of leading antibody development and production companies, highlighting contact information, business summary, product pipelines, clinical development status, intellectual property estate, alliances, financial status, and information on management.

Analysis of the business trends, strategic issues, therapeutic prospects, and market prognosis, highlighting trendsetting technologies and companies.

Available in two formats: CD-ROM or PRINTED

Price: $4,950.00

Please contact me to discuss this report

CD-ROM Format Printed Format CD+Printed Format

Publication date: September 2001

Number of pages: 369 Pages, 85 Exhibits, 35 Companies Profiled

Over the last decade, a global threat to public health has continued to rise, and in fact, will worsen in future decades unless effective antiviral therapies are introduced. For example, approximately two billion people are infected with the hepatitis B virus globally. Of those infected, between 300-350 million are chronic carriers of the virus but remain asymptomatic. Even in the U.S., where the hepatitis B vaccine has been available since the early 1980s, an estimated one million people are carriers of the hepatitis B virus, and the number of chronic carriers is expected to grow to 1.7 million by 2010.D&MD's Market Analysis Report, Antivirals: Technologies, Trends, and Market Opportunities, will bring you up to date by assessing the latest trends, technologies, and strategies in the antivirals industry. New targets for antiviral agents are examined, and key pharmaceutical company alliances identified.New drugs are urgently needed to combat viral diseases and resistant viruses. More importantly, scientific methods to continually discover replacement drugs are necessary; each time a new antiviral is developed using currently popular approaches, there will undoubtedly be resistance. New technologies have the potential to change this by providing information that can be developed into new antiviral strategies. The future promises great opportunities for innovative companies that remain at the forefront of drug discovery technology. D&MD's Antivirals Report will provide you with the tools to stay ahead of the competition.

Unique Benefits

Analysis of current industry trends and strategies, providing insight into potential sales and profits for your business

Assessment of the latest technologies impacting existing antivirals, identifying new opportunities to overcome the issue of resistance

Examination of the new targets for novel antiviral agents revealed by genomics, recognizing their affect on the future of the market

Discussion of market and technology trends within the antiviral industry, presenting the information needed for successful strategic planning and collaborative opportunities

Evaluation of key pharmaceutical company alliances, identifying successful partnerships to benchmark future deals

Available in twoformats: CD-ROM or PRINTED

Price: $4,950.00

Please contact me to discuss this report

CD-ROM Format Printed Format CD+Printed Format

Publication date: October 2001

Number of pages: 200+ Pages, 40+ Companies Profiled

Lung cancer is the second most commonly occurring non-cutaneous cancer and the leading cause of cancer deaths in the United States. Worldwide the incidence rates vary; however, lung cancer remains a leading cause of cancer mortality-reported by the World Health Organization to have caused 1.1 million deaths in 1997. Current treatments are, for the most part, ineffec-tive; the five-year survival rate for lung cancer patients has remained unchanged at 14% for the last twenty years.

Lung cancer is a disease with a dismal prognosis. Patients usually have advanced disease at diagnosis. New therapeutic options range from modifications of conventional drugs that improve their pharmacokinetic properties to novel classes of drugs such as antisense molecules, anti-angiogenic agents, and drugs that induce targeted apoptosis. As these innovative solutions complete the regulatory process, the options for lung cancer patients will expand, and hopefully, for the first time in more than twenty years, the mortality figures will improve.

D&MD's Lung Cancer Market Analysis Report will detail the current and future potential treatments for this deadly disease. Additionally, the Report analyzes the future in detection and screening.

Unique Benefits of the Report Include:

Discussion of the causes and pathology of lung cancer, providing a vital overview of the disease

Analysis of the current therapeutic options and in-depth discussion on promising experimental approaches, detailing existing and emerging trends

In-depth company profiles outlining the business focus, contributions to the field, and research and development pipelines, giving a clear competitive landscape for potential collaborations and business strategies

Discussion of the most promising products in late-stage development, giving insight into the next generation of lung cancer pharmaceuticals

Available in twoformats: CD-ROM or PRINTED

Price: $4,950.00

Please contact me to discuss this report

CD-ROM Format Printed Format CD+Printed Format

By David Q. Anderson, Ph.D., MBA

Publication date: July 2001

80+ Pages, 30+ Exhibits:

D&MD's Compound to Capital - Financing Biotech is essential reading for biotechnology executives grappling with the problem of making their companies attractive to the private and public capital markets in light of the recent economic downturn. This Publication will prove a valuable tool for an industry seeking to re-invent itself in the wake of the genomic boom, and assess the positioning that companies must follow in order to ensure success in a crowded marketplace.

The investment industry has seen some dramatic changes in the last 12 months with the return of the bear market. Investment professionals will find value in this publication as it explains the intricacies of the biotechnology industry and will help to differentiate this technology from the other high technology stocks on the market. As the biotechnology industry matures and more and more companies are reaching profitability, the sector is proving to be a successfull investment vehicle for those investors that understand the industry, technologies, business models, and long-term requirement for an investment. With a strong content-base supplied by IBC USA's 2001 BioInvestment Forum, enhanced through one-to-one interviews with the expert faculty, D&MD's Compound to Capital will provide investment bankers and venture capitalists a view on the industry and a glimpse at the business models being followed by the most successful companies.

Represenatives from the following companies and institutions contributed to the Publication:

ACLARA Biosciences

Atherogenics

Boston Healthcare Associates

CIBC World Markets

Cordova Ventures

First Union Securities

Forward Ventures

MolecularWare

Oxford Bioscience Partners

Polaris Associates International

Roth Capital Partners

The Lion Consulting Group
View Table of Contents

DM&D Focus Report

Publication date: July 2001

The drug delivery field presents a growth opportunity driven by the introduction of increasing numbers of biotechnology-based therapeutics. The burgeoning value of drug delivery systems is so great, in fact, that the major pharmaceutical and biotechnology companies are expanding into this arena, and many drug delivery companies are becoming involved with pharmaceutical development and marketing. Everyone is seeking ways to match key drugs to the perfect mode of delivery.

Furthermore, pharmaceutical companies are finding that novel delivery technologies can extend the patent life span of drugs, thus expanding their commercial potential. And there are now drug delivery methods in development that will make essential pharmaceuticals available where traditional vaccines are sporadically available if at all.

In D&MD's latest Focus Report-Vaccines and Beyond: Novel Drug Delivery Methods for Modern Pharmaceuticals-D&MD Newsletter's most experienced pharmaceutical and biotechnology analysts join with some of the world's leading research innovators to describe the major events that have driven progress in traditional drug delivery technology, examine the successes and failures that have been experienced to date in creating new drug delivery systems, and describe what lies ahead for the field.

Learn About These Key Drug Delivery Trends:

edible vaccines

microsphere technology

single-dose vaccines

lipid-based delivery systems

specialized oncological and CNS drug delivery

DNA vaccines

and more!

D&MD's latest Focus Report is a compilation of some of the best recent articles from D&MD Newsletter and related sources, intended to give you information about the recent innovations and opportunities in vaccines and other drug delivery methods.

Vaccines and Beyond: Novel Drug Delivery Methods for Modern Pharmaceuticals will interest anyone who works in drug discovery and development, especially in those areas relating to cancer and neurological disease, and who is interested in the value of cost-effective drug delivery. The chapters in this Focus Report will enhance your understanding of the progression of drug delivery technologies, which strategies have and have not made sense, and why the decisions you make today will affect your profitability for years to come.
View Table of Contents

DM&D Focus Report

Publication date:September 2001

Drug Discovery Technologies & Strategies 2001: Increasing Efficacy and Profitability will interest anyone who works in drug discovery and development. No matter which area of therapeutic expertise you specialize in, the chapters in this Focus Report will enhance your understanding of the progression of drug discovery technologies, which strategies have and have not made sense, and why the decisions you make today will affect your profitability for years to come.

The technological components of the drug discovery enterprise are diverse and growing rapidly in number, leaving many pharmaceutical companies to re-evaluate which methods work best for delivering sound, profitable drugs that they can bring to market. In many cases, it is no longer sufficient-or even wise-to maintain large libraries of compounds in which one hunts for druggable molecules as a miner digs for golden nuggets at the base of a barren mountain. Instead, pharmaceutical leaders are finding that novel discovery and validation technologies can expand the hit rate for promising compounds, thus reducing the costs associated with failures lurking in the pipeline and expanding the commercial potential of efficacious new drugs.

In D&MD's latest Focus Report-Drug Discovery Technologies & Strategies 2001: Increasing Efficacy and Profitability-D&MD Newsletter's most experienced pharmaceutical and biotechnology analysts combine to describe the major events that have driven progress in traditional drug discovery technology, examine the successes and failures that have been experienced to date in validating new drug discovery paradigms, and relate what may lie ahead for the industry.

D&MD's latest Focus Report is a compilation of some of the best recent articles from D&MD Newsletter and related sources, intended to inform you of the current motivations and opportunities within drug discovery.

Learn about these fundamental discovery technologies:

Biochips

Bioinformatics

Epigenetics

Formulations

High-Throughput Genomics

High-Throughput Screening

Pharmacogenomics

Proteomics

Single Nucleotide Polymorphisims

Tissue Bioreactors
View Table of Contents

Publication date: June 2001

Number of pages: 200 pages, 30 company profiles, 15 exhibits.

D&MD projects a substantial increase in the number of respiratory disease therapeutics with novel drug targets in clinical trials in the near future.

The number of people suffering from respiratory diseases worldwide is estimated to exceed one billion, with approximately 30 million individuals living with a chronic respiratory disease in the United States alone. The prevalence of asthma in the US rose by 59% between 1982 and 1996, with the highest rate of increase seen in the 18 to 44 year old group, thus verifying the alarming rate at which these diseases are rising.

D&MD's Report Respiratory Diseases: Current and Future Therapeutic Approaches and Market Opportunities provides an understanding of the largest segments in the respiratory diseases marketplace by discussing the causes, incidence, commonly used treatments, market size, and novel advances in therapeutics and drug delivery of products.

The leading respiratory diseases discussed are:

Asthma

Chronic Obstructive Pulmonary Diseases (emphysema and chronic bronchitis)

Cystic Fibrosis

Respiratory Syncytial Virus (a major cause of cough, cold, and bronchiolitis)

Respiratory diseases are among the most rapidly expanding of all, yet the methods of treatment have made minimal advancements.

Opportunities in the therapy of respiratory diseases are due to rise substantially as the number of successful clinical achievements are projected to increase in the near future.

Unique Benefits of this Report Include:

» Discussion of the major disease states, therapeutics, and current players, providing insight into the respiratory disease market.

» Examination of key technologies currently in the clinical development stage and those recently approved for use, identifying advancements within the industry.

» Review of statistics on the major respiratory diseases frequently targeted by biotechnology and pharmaceutical companies developing novel therapeutics, giving an in-depth look at the progression of these diseases and their treatments.

» Overview of the market drivers for the development of novel therapeutic products to treat respiratory diseases, highlighting potential areas of opportunity.

» In-depth company profiles describing the business strategies, financial positions, and research and development pipelines of key industry leaders within the respiratory disease market, identifying the strategies of these leading players.

Genentech, ICOS, IDEC Pharmaceuticals, Immunex Corporation, Inflazyme Pharmaceuticals, Inhale Therapeutic Systems, Inspire Pharmaceuticals, IVAX Corporation, ,Magainin Pharmaceuticals, Medimmune, Millennium Pharmaceuticals, Rigel Pharmaceuticals, Sepracor, Sheffield Pharmaceuticals, Tanox Biosystems, Targeted Genetics Corporation, Texas Biotechnology Corporation, Valentis, ViroPharma.

Available in two formats: CD-ROM or PRINTED

Price: $4,950.00

Please contact me to discuss this report

CD-ROM Format Print Format

by Pamela Bassett, D.M.D, M.B.A.

Publication date: July 2001

Number of pages: 500 pages, 50 company profiles, 50 exhibits.

Sales of antibacterials and antifungals worldwide are approaching $26 billion annually, of which $7 billion are injectables. Historically, sales of cephalosporins maintained the largest market share. Recently, however, the introduction of new fluoroquinolones and a ketolide, a new antibiotic class, promise to exceed sales of all other classes. New antibiotics and antifungals, like the echinocandins, will continue to cause rapid shifts in market share as the demand for more effective therapies expands. One hundred of the antibacterial agents on the market today were developed by using variations on just nine basic elements. Today, genomics and high-throughput screening are yielding potential antibiotics and antifungals utilizing previously unknown mechanisms of action. D&MD's Report Antibacterials and Antifungals, 2nd Edition provides the answers to help pharmaceutical and biotechnology firms develop numerous strategies to exploit their market positions and develop technological strengths.

Over the last decade, the rapid rise in severe and fatal infections caused by drug resistant bacteria has posed a threat to public health globally. In addition, various factors are fostering the emergence of new and more threatening infectious diseases. These factors include:

Overuse and misuse of antibiotics

Expanding use of child care facilities

Aging of the population

Growth in the immunosuppressed patient population:

HIV infection

Organ transplantation

Chemotherapy

Globalization of the food supply - Changes in dietary habits, food processing and packaging

New drugs are urgently needed to combat drug-resistant bacteria. More importantly, scientific methods to continually discover replacement drugs are necessary; each time a new antibiotic is developed using approaches popularized in the past 40 years, there will undoubtedly be resistance. New technologies can change this by providing information that can be developed into new antibacterial and antifungal strategies. The future promises great opportunities for innovative companies that remain at the forefront of drug discovery technology. D&MD's Antibacterials and Antifungals Report provides the reader with the tools to stay ahead of the competition.

Unique Benefits of this Report:

» Detailed analyses of current industry trends and strategies to provide insight into potential sales and profits for your business.

» Coverage of the latest technologies impacting existing antibacterial compounds, to help identify new opportunities and overcome the issue of resistance.

» New targets for novel antibacterial agents revealed by genomics and their affect on the future of the market.

» In-depth market and technology trends, to assist in future strategic planning and finding opportunities for new collaborations.

» Sales forecasts through 2006 (by antibacterial class) to gauge industry growth and investment strategies.

» Comparisons of key pharmaceutical company alliances to identify successful partnerships and to benchmark future deals.

» A Sample Listing of Companies Profiled: Abbott Laboratories, Alpharma, Alza, AM-Pharma, American Home Products, Antex Biologics, Aronex, AstraZeneca, Aventis, Bayer AG, BioDelivery Sciences, Bristol-Myers Squibb, British Biotech, Chiron, Cubist Pharmaceuticals, Daiichi Pharmaceuticals, Dainippon Pharmaceutical, Eli Lilly, Faulding, Fujisawa, Ganeden Biotech, Genome Therapeutics, Gilead Sciences, GlaxoSmithKline, Hoffmann-La Roche, Ibis Therapeutics, Johnson & Johnson, Kyowa Hakko Kogyo, Mieji Seiki, Kaisha SP, Merck, Microcide Pharmaceuticals, Micrologix Biotech, Millennium Pharmaceuticals, Mycota Biosciences, Mylan, NewBiotics, Novartis, Novavax, Pfizer, Phage Therapeutics, Pharmacia, Phytera, Sankyo, Schering Plough, SIGA Technologies, StressGen, Taisho Pharmaceutical, The Liposome Company, Tularik, Unimed, Versicor, Xoma,

Available in two formats: CD-ROM or PRINTED

Price: $4,950.00

Please contact me to discuss this report

CD-ROM Format Print Format

by Gordon Blackwell, M.Sc.

Publication date: April 2001

Number of pages: 400 pages, 100 company profiles

Specialist technology companies are likely to become the powerhouse of drug discovery over the next few years.

In recent years, the advent of a whole range of new technologies, such as biotechnology, combinatorial chemistry, high-throughput screening, genomics, proteomics, and more, has created the foundation needed to discover more drugs faster and cheaper. These developments can be considered the First Discovery Revolution, which integrated the various elements of the drug discovery process into a single umbrella of information. To ensure that the benefits of this integration are forthcoming, what is now needed is the Second Discovery Revolution.

The Second Discovery Revolution must be concerned with taking a fresh look at the management and process of drug discovery. The specialist discovery companies that emerged during the First Revolution are able to outsource these new techniques to the pharmaceutical sector. This novel approach to the industry has begun to break down technology boundaries, allowing data to move freely and enhance its global perspective. The overlapping of these boundaries should eventually produce a new breed of scientists able to oversee the entire drug discovery process, thus forming solid alliances, a shared investment risk, and access to a wide range of expertise. This will ultimately attract investors through an effective drug discovery process and a full pipeline. D&MD's Drug Discovery Marketplace Report provides an assessment of how the major pharmaceutical companies are planning, organizing, and operating their drug discovery programs for this Second Discovery Revolution. In this vital new Report, key market trends are identified and upcoming developments forecasted.

Unique Benefits of this Report:

» Examination of the development and promising benefits of the technologies from the First Discovery Revolution, supplying the background needed to move forward in the industry.

» Analysis of how major industry players are planning and organizing their drug discovery processes, providing insight into the means for their success.

» Identification of key market trends, helping the reader decide how to proceed in this industry.

» Review of the operation of drug discovery specialist companies, giving insight into the methods of these highly valuable industry contributors.

» In-depth profiles of drug discovery and biotechnology companies, identifying chief positions and strategy insights.

3-Dimensional Pharmaceuticals, Abbott Laboratories, Affymax Research Institute, Affymetrix, Agouron Pharmaceuticals, AGOWA GmbH, ALZA Corporation, American Home Products, Amgen, Applied Biosystems, ArQule, AstraZeneca, Atherogenics, Aurora Biosciences Corporation, Aventis, Axcell Biosciences, Axys Pharmaceuticals, Bayer, Biacore AB, BioChem Pharma, BioFocus, Biogen, Bristol-Myers Squibb, British Biotech, Cadus Pharmaceuticals Corporation, Caliper Technologies Corporation, Cambridge Antibody Technology Group, Cambridge Drug Discovery Limited, Celera Genomics, Cellomics, Celltech Group, Chemnavigator, Compugen, COR Therapeutics, Corixa, CuraGen Corporation, Cytogen, cytoGenix, Discovery Partners International, Eli Lilly, Evotec BioSytems AG, Fujisawa, Gene Alliance, Gene Logic, Gene Quest, Genelabs Technologies, Genentech, Geneva Bioinformatics (GeneBio) S.A, Genome Therapeutics Corp, Genset SA, GlaxoSmithKline, Hyseq, Illumigen Biosciences, Incyte Pharmaceuticals, Inflazyme Pharmaceuticals, Isis Pharmaceuticals, Johnson & Johnson, LabOnWeb, LifeSpan BioSciences, Magainin Pharmaceuticals, Merck & Co, Microcide Pharmaceuticals, Millennium Pharmaceuticals, Molecular Devices Corp, Molecumetics, Myriad Genetics, Neurogen Corporation, NPS Pharmaceuticals, Novartis, Onyx Pharmaceuticals, OSI Pharmaceuticals, Oxford Asymmetry, Oxford GylcoSciences, Oxford Molecular Group, PE Corporation (now Applera Corporation), Pfizer, Pharmacia, Pharmacopeia, Phoenix International, Proteome, Protherics, QIAGEN GmbH, RepliGen Corporation, Ribozyme Pharmaceuticals, Roche, Rosetta Inpharmatics, Sangamo Biosciences, Schering Plough, Sepracor, SNP Consortium, Structural Bioinformatics, Takeda, Texas Biotechnology Corporation, Tredegar Corporation, Triangle Pharmaceuticals, Tularik, Valentis, Vertex Pharmaceuticals, ViroPharma, Vyrex Corporation, Xenova Group, ZymeTx

Available in two formats: CD-ROM or PRINTED

Price: $4,950.00

Please contact me to discuss this report

CD-ROM Format Print Format

Written by a team of Ph.D. Level Industry Analysts

Publication date: March 2001

Number of pages: 400 pages, 30 company profiles, 30 exhibits

Identification of targets for drug development and the discovery of therapeutics are being transformed by bioinformatics. D&MD's Bioinformatics Market Analysis Report assists in determining the best methods to incorporate and utilize bioinformatics to achieve and sustain a competitive advantage in this space. This Report examines the evolution of bioinformatics and the current status of the technology and its impending consequences.

Bioinformatics stands at the interface of molecular biology and information sciences, where it promises to provide critical tools for managing the immense volume of biological information. Last year, the Human Genome Project unlocked the DNA code for 23 human chromosomes. Contained within are millions of potential genetic markers for the development of new drugs and other treatments for disease. Making sense of all that data is the job of bioinformatics companies and requires some advanced computing muscle to do it.

The tools that comprise bioinformatics are themselves testament to the explosion of diversity that is present in the drug discovery industry. Just a few years ago, the only tractable experiments were intelligent chemical trial-and-error followed by extensive in vitro and in vivo testing. The 70's decade of analogue bashing gave way to the 80's rational drug design. The 90's revolution of biotechnology and new measurement technology has spawned new technologies and industries focused on in-silico and on-silico biology.

The prospects for bioinformatics are inseparable from the prospects and market structure of biotech, so a large amount of the equity investment in biotech during 2000, totaling $31 billion, flowed into bioinformatics. Overall, it is estimated that the pharma sector spends 6% of its $9 billion annual drug discovery budget on IT. That's $500 million per year. Suppliers such as MDL, Molecular Simulations, Tripos, and Oxford Molecular have grown and generate revenues between $20 million and $70 million. Oxford Molecular predicts a total market for its services totaling $1.3 billion by 2002 with 75% accessible from their own products. Other sources suggest an even larger market, moving to $10 billion in five years.

D&MD's Bioinformatics Report is the only report you need to carefully guide you through this competitive and challenging area.

Unique Benefits of this Report:

» Up-to-date analysis of the various technologies, databases, and algorithms that are being deployed in bioinformatics today, giving insight into the current technology marketplace.

» Discussion of the market environment, including future predictions of technology trends of computer languages that are being used in the genomics-driven drug discovery landscape, detailing where the industry is going.

» Details of current venture capital breakout, presenting the market opportunities in bioinformatics.

» Comprehensive profiling of the leading players in the bioinformatics market, presenting unbiased analysis of the competitive environment.

» Analysis of the alliances and partnerships occurring to date, illustrating the successful strategies and collaborations.

Available in two formats: CD-ROM or PRINTED

Price: $4,950.00

Please contact me to discuss this report

CD-ROM Format Print Format

by Gerry Harnisch

Publication date: June 2001

Number of pages: 200 pages, 25 company profiles, 40 exhibits

Global drug sales through retail pharmacies amounted to $223.6 billion in the year ending February 28, 2001. The market for branded drugs currently used to treat CHF in the US is worth nearly $430 million alone. The top ten brands are together worth over $327 million, representing 76.2 percent of its market share.

It is foreseen that the CHF market is about to undergo great changes due to an increasing prevalence of the disease and the use of current and novel treatments by physicians. For these reasons, analysts predict that the global CHF market will exceed $4 billion within the next few years. D&MD's Congestive Heart Failure Report will provide you with the information needed to position your company for success in this growing market. Now is a great time to enter the market that promises such remarkable rewards!

Congestive heart failure (CHF) is a widespread illness, affecting nearly five million Americans. CHF is the only cardiovascular disease that is continuously increasing worldwide, largely due to an older population and improved secondary prevention of acute myocardial infarction and hypertension. According to the American Heart Association, deaths resulting from CHF increased by well over 100 percent between 1979 and 1998. Even with recent improvements in the treatment of CHF, it remains a disappointing prognosis.

D&MD's Report, Congestive Heart Failure: Advances in Treatment and Their Market Potential, provides an overview of this expanding disease. Current and emerging treatments are reviewed, and opportunities in the current drugs' market are explored.

Unique Benefits of this report include:

» Comprehensive discussion of the background, pathophysiology, and diagnosis of congestive heart failure, providing an overview of this devastating disease

» Detailed review of the current pharmacological and nonpharmacological therapeutic treatments for CHF, identifying today's practiced methods

» Full evaluation of emerging pharmacological treatments that may reach the market, forecasting peak sales and areas of opportunity

» Thorough analysis of the current global drugs market and the market for branded CHF drugs in the US, highlighting existing opportunities and their potential

» In-depth profiles of companies with new pharmacological treatments for CHF in development, identifying the strategy of key industry players: Abbott Laboratories, Actelion Ltd., Alexion Pharmaceuticals, AstraZeneca, Banyu Pharmaceutical Co. Ltd., Biogen, Bristol-Myers Squibb, Celgene Corporation, Celltech Group plc, Centocor, Chiesi Farmaceutici S.p.A., CV Therapeutics, Genentech, Medigene AG, Mitsubishi-Tokyo Pharmaceuticals, Myogen, NitroMed, Novartis, Orion Corporation, Pfizer, Pharmacia Corporation, Sanofi-Synthélabo, Scios, Shire Pharmaceuticals Group plc, Takeda Chemical Industries Ltd., Texas Biotechnology Corporation, Yamanouchi Pharmaceutical Co. Ltd.,

Available in two formats: CD-ROM or PRINTED

Price: $4,950.00

Please contact me to discuss this report

CD-ROM Format Print Format

by Katherine Sheldon Ph.D.

Publication date: June 2001

Number of pages: 200+ Pages, 35 Companies Profiled, 10+ Treatment Strategies Outlined

Breast cancer is the second leading cause of cancer deaths in women in the U.S. Worldwide, mortality rates vary with geographical location, but overall, this disease has a significant global impact. Breast cancer incidence rates increased steadily throughout the 1980s, and leveled off in the 1990s. As the population continues to age, the incidence of new breast cancers will rise. This will ultimately lead to the subsequent demand for accurate screening and effective treatments, thus facilitating the entry of next generation cancer therapeutics into the market.

D&MD's Report, Breast Cancer: Market Opportunities for Novel Diagnostic and Therapeutic Approaches, provides a detailed description of the current options available for disease management and explores the market opportunities for novel therapeutic and diagnostic approaches.

Unique Benefits of this Report Include:

» Discussion of the causes, pathology, and epidemiology of breast cancer, providing a vital overview of the disease

» Evaluation of current therapeutic and diagnostic options available in the treatment of breast cancer, outlining today's practiced methods

» Analysis of the biochemistry behind current and experimental approaches for the prevention and treatment of breast cancer, identifying key ammunition in the battle against this disease

» Company profiles outlining the business focus, contributions to the field, research and development pipelines, and financials, highlighting industry leaders and strategy insights

» Review of the technological challenges associated with reducing the incidence and mortality of breast cancer, recognizing possible hurdles to overcome

» Discussion of the most promising development stage products expected to reach the market in the next few years, putting you ahead of the competition

In-Depth Company Profiles: Aronex, AstraZeneca, Aventis Pharma, Biomira, Bristol-Myers Squibb, Cell Pathways, Cell Therapeutics, Celsion, Computerized Thermal Imaging, Corixa, Cytoclonal Pharmaceuticals, Eli Lilly, EntreMed, Eos Biotechnology, F. Hoffmann-La Roche, Genentech, Genta, Geron, Hybridon, Immunomedics, Immusol, IMPATH, Matritech, Myriad Genetics, Novartis AG, Orion Pharma, OSI Pharmaceuticals, Pharmacia Corporation, Pharmacyclics, Ribozyme Pharmaceuticals, Scantek Medical, Titan Pharmaceuticals, TransScan Medical Ltd., Tularik, Vertex Pharmaceuticals, Vysis.

Available in two formats: CD-ROM or PRINTED

Price: $4,950.00

Please contact me to discuss this report

CD-ROM Format Print Format

by Mary J. Ortner, Ph.D., M.B.A.

Publication date: January 2001

Number of pages: 400+ Pages, 70+ Exhibits, 30+ Companies Profiled

Gene therapy is being actively researched in almost every serious disease.

The 21st Century is upon us and the sequencing of the human genome has brought incredible challenges concerning how this information will be used. The number of discrete genes in the human being has been estimated to be between 100,000 and 140,000, most of which have already been isolated. Although the vast majority have not been functionally identified, numerous genes have been directly implicated in disease function or inherited disorders. For decades, scientists have dreamed of curing such catastrophic conditions in the most simple and elegant manner - by replacing these malfunctioning genes. That dream is now becoming a reality.

Gene Therapy: Medicine and Commerce for the 21st Century is the sequel to the well-acclaimed second edition of D&MD's Human Gene Therapy Report. Focusing on the most recent developments in this entirely new world facing the pharmaceutical, medical and investment communities, this report is aimed at the business and science professional alike. D&MD's Gene Therapy Report will help the reader understand the science of gene therapy along with a realistic view of the field and its future. It will also show how independent companies and those affiliated with Big Pharma are pursuing paths to the prize that will, once and for all, demonstrate the ellusive proof of principal.

Unique Benefits of this Report:

» Introduction to the functioning of genes and gene therapy, providing the background needed to put key issues into perspective

» Description of both disease-targeted preclinical and clinical research, giving insight into the novel trials in several disease areas

» Analysis and comparison of several gene delivery research methods, helping the reader decide which is most appropriate

» Examination of the critical areas of gene therapy research, giving the reader an understanding of advances yet to come

» Discussion of the ethical issues surrounding gene therapy research, educating the reader in this area of research and the clinical manifestations of its outcomes

» Exploration of the impact of current USPTO regulations on intellectual property and of stacking patents on the industry and its future

» Discussion of current investor attitudes and the business models now favored by gene therapy companies, giving the reader insight into where to proceed in this industry

» Comprehensive analysis of the regulatory ramifications of the industry, helping the reader avoid legal pitfalls and consequences

» Many gene therapy and business information resources are provided, helping the reader keep up-to-date in this fast paced, ever changing environment

» In-depth profiles of 34 business and scientific gene therapy companies, identifying chief positions and strategy insights

Available in two formats: CD-ROM or PRINTED

Price: $4,950.00

Please contact me to discuss this report

CD-ROM Format Print Format

by Ken Rubenstein, Ph.D.

Publication date: May 2000

Number of pages: 250+ Pages, 50+ Exhibits, 40+ Companies Profiled

The problem of pain is huge; the numbers affected, staggering. In many cases the pain is manageable with drug or adjunctive therapies, yet millions each year experience unrelieved suffering. Progress is needed in better application of existing therapies, and the medical community has responded by adding pain training to medical curricula and establishing pain management as a growing and respected medical specialty.

D&MD Reports' second edition of its best-selling report Pain Therapeutics is completely revised and updated.

Unique benefits of this report include:

» An initial section defining the problems of pain management and laying down the background needed to put key issues in perspective.

» In-depth examination and explanation of revolutionary research providing the understanding of pharmaceutical advances yet to come.

» Market and competitive analysis delineating the commercial players, their strategies, and activities.

» In-depth company profiles providing complete pictures of pain-related activities of companies, both large and small, dealing with the discovery and development of drugs, delivery formats and devices.

» Analysis of market trends and future developments in both therapeutics and markets by segment with growth projections through 2004.

Even if existing therapies were applied perfectly, deficiencies in pain management would continue unabated. Existing pain drugs, many of which were initially developed for other indications, are often inadequate for the task. Morphine and related opioids shut down respiratory and digestive functions. NSAIDs have been responsible for the deaths of more than 16,000 Americans annually, and even the promising selective COX-2 inhibitors may fall short of eliminating gastrotoxicity.

Lack of understanding pain mechanisms at the molecular level has prevented the identification of suitably specific new targets for the development of high efficacy, low toxicity drugs. However, that situation is improving rapidly as basic researchers quickly fill in huge knowledge gaps by pinpointing key receptors and predicting the sorts of interventions that can shut down pain without interfering with other critical body functions.

A new generation of painkillers derived from the earliest findings of this research revolution is currently in clinical trials and promises to keep pain drug sales growing at a good rate.

But the best is yet to come as new target discoveries begin to generate new drug leads, accelerated by industrialized discovery and development enterprises. The second decade of the new millennium promises major advances in pain management, together with the establishment of analgesia as one of the leading sectors in the pharmaceutical market.

D&MD's Pain Therapeutics, 2nd Edition is the report that presents the complete picture of this marketplace.

In-depth Company Profiles: Abbott Laboratories, Adolor Corporation, Algos Pharmaceutical, Alpharma, Alza Corporation,

American Home Products, Anesta Corporation, AstraZeneca, plc, BioMatrix, Inc., Biovail Corporation International, Bristol-Myers Squibb Company, Cambridge NeuroScience, Celltech Group plc, CoCensys, Inc., Elan Corporation plc, EMPI, Inc., Endo Pharmaceuticals, Inc., EpiCept Corporation, Gensia Sicor Pharmaceuticals, Inc., Glaxo Wellcome, plc, Henley HealthCare, Inc. , Hoffmann-La Roche, ICAgen, Inc., Johnson & Johnson, Inc., Mallinckrodt, Inc., Merck & Co., Inc., Monsanto Company (G.D. Searle & Co.), Myelos Neurosciences Corp., Neurobiological Technologies, NeuroSearch A/S, NicOx S.A., nitroMed, Inc., Novartis, NovaTelligence, Inc., NPS Pharmaceuticals, Inc., Pain Therapeutics, Inc., Perrigo Co., Pfizer, Inc., Rehabilicare, Inc., Sepracor, Inc., Sheffield Pharmaceuticals, Inc., SmithKline Beecham plc, Trega Biosciences, Inc., Watson Pharmaceuticals, Inc.,

Available in two formats: CD-ROM or PRINTED

Price: $4,950.00

Please contact me to discuss this report

CD-ROM Format Print Format

by Alex D. Kanarek, Ph.D.

Publication date: October 2000

Number of pages: 450 Pages, 70+ Exhibits, 60+ Companies Profiled

Global markets approximating $40 billion currently exist for highly purified antibodies, growth factors, cytokines, hormones, vaccines and a host of new recombinant proteins and peptides. US biopharmaceutical companies at present have revenues exceeding $16 billion from such products, and this sum is expected to increase to $86 billion by 2025. Within a decade, approximately 25% of all drugs on the market in developed countries are expected to fall into this category, as the full impact of genomics research and development is felt and the number of candidate therapeutic targets is dramatically increased.

Against the pressure of this tide of new product introductions will stand the dike erected by the healthcare providers, who are forcing manufacturers to reduce the cost of drugs. Further obstacles in product development are provided by regulatory bodies demanding better characterization and higher purification of biologicals incorporated in new therapeutics, prophylactics and diagnostics.

The companies providing goods and services in bioprocessing are at the forefront of this development movement. Some are already gaining increased revenues from improvements in current processes or in the introduction of new technologies in areas such as expression systems, fermentation, cell separation, filtration, chromatography and in all types of analytical technology.

D&MD's latest report, The Bioprocessing Industry: Growing Markets in BioPharm Manufacturing Technology, is an in-depth analysis of this multi-billion dollar industry, the companies that make up its major segments and the technologies that are their stock-in-trade.

D&MD's Bioprocessing Report delivers to the reader a well-organized package of comprehensive information from an expert in the field. It would take a substantial amount of time to research, gather and analyze the basic information of the various elements of the bioprocessing industry...D&MD has done this for you. This is THE report you need to understand the fundamentals of this evolving industry!

Unique Benefits of this Report:

» An introduction and overview of the Bioprocessing Industry providing the background needed to put key issues in perspective.

» Examination of new technologies in areas such as expression systems, fermentation, cell separation and chromatography providing an understanding of advances yet to come.

» Market and competitive analysis delineating the commercial players, their strategies and special niche markets.

» In-depth company profiles, including contact information, business summary, product summary, financials and key management, highlighting those companies occupying leading positions.

A Sample List of Companies Profiled: Agilent Technologies, Alfa Laval AB, Amersham Pharmacia, Bio Science Contract Production Corporation, Bio-Rad Laboratories, BioReliance Corporation, Cambrex Corporation, Charles River Laboratories, Covance, CSL, DSM Biologics, Genzyme Transgenics Corporation, Getinge/Castle, Invitrogen Corporation, Life Technologies, MDS PanLabs, Millipore Corporation, New Brunswick Scientific, Pall Corporation, PE Biosystems, Perbio Science AB, PPL Therapeutics, Prometic Biosciences, Sartorius AG, SP Industries, Spectrum Laboratories, STERIS, Sybron Corporation, TosoHaas, Waters Corporation.

Available in two formats: CD-ROM or PRINTED

Price: $4,950.00

Please contact me to discuss this report

CD-ROM Format Print Format

G Thor, Ph.D.; J Terryberry, B.S.; R Pottathil, Ph.D.; J Voland, M.D.

Publication date: July 2000

Number of pages: 500 Pages, 40+ Exhibits

Sequencing of the human genome has drastically altered medical diagnosis and the pharmaceutical sciences. This torrent of information has changed our ideas of psychiatric diseases such as depression and anxiety, and given us a clearer understanding of inborn errors of metabolism. Twenty years ago diseases like Tay-Sachs were based on purely clinical descriptions, confusing even to the experts and giving little insight into the pathogenesis of the disease.

Today the genes responsible for the syndrome have been characterized, the mutations underlying the disease have been mapped and diagnostic tests are available which can predict with a high degree of certainty the phenotype of an affected child. While it would be a major challenge to treat a lethal recessive disease such as Tay-Sachs with pharmaceutical intervention, these types of diseases provide superb models to investigate molecular diagnosis, genetic mechanisms and novel therapies. The genome project has started to provide the equivalent information for treatable diseases such as:

Depression

Learning disorders

Epilepsy

Infectious diseases

Tumors

D&MD's From Molecules to Medicines: Future Opportunities in Developmental Neurologic and Psychiatric Diseases Report is aimed at both the business and science professionals with a balanced attention to the research and commercial aspects of developmental neurologic and psychiatric diseases. These diseases provide abundant opportunities for those willing to look at diagnosis and treatment from a novel perspective. The diseases of the nervous system are rapidly succumbing to molecular and genetic analysis. The human genome project, along with the sciences of genomics, proteomics and bioinformatics, are providing breakthroughs in understanding diseases of the brain, and health and commercial benefits are within reach.

This report focuses on these main areas:

Congenital Diseases of the Nervous System

Psychiatric Disorders

Pervasive Developmental Disorders, Learning and Speech Disorders

Developmental Neuro-Oncology

Environmental and Toxicological Disturbances

Epilepsy and Vigilance Disorders

Viral Infections Resulting in Neurological Disorders

Neurogenetic Disorders

Lysosomal Storage Diseases

Each chapter is a separate entity, authored by experts in their respective fields including pediatric pathology, biochemistry, molecular genetics, diagnostic neuropathology and virology. Multiple authors allow the report to approach neurologic psychiatric diseases and pharmaceutical interventions from several different perspectives. It provides clinical data, cutting-edge research, current trends in ongoing projects in major pharmaceutical and biotechnology research of the most common diseases affecting the developing nervous system. Hundreds of comprehensive, current relevant references from journals and web sites are provided.

This D&MD Report helps the reader discover many of the pharmaceutical, neurologic and psychiatric-oriented sites, including government, educational, commercial, journals/periodicals, clinical databases, institutes and link-listings, useful for remaining informed of current status and obtaining information in this fast-paced, ever- changing environment.

Company Profiles: Abbott Laboratories, Allelix Biopharmaceuticals, Inc., AstraZeneca, American Home Products Corp., Boston Life Sciences, Inc., Cambridge NeuroScience, Inc., CeNeS Limited, Cephalon, Cerebrus, CoCensys, Cortex, Cypros, CytoTherapeutics, Eli Lilly and Co., Glaxo Wellcome plc, Gliatech, Guilford, Hoechst Marion Roussel AG, Interneuron, Janssen Pharmaceuticals, Johnson & Johnson, Kanebo Ltd., Lundbeck, Merck & Co, Merz & Co. Gmbh, Monsanto/G.D. Searle, Neurobiological Technologies, Neurocrine Biosciences, NeoTherapeutics, Novo Nordisk, Ono Pharmaceutical, Pfizer, Pharmacia & Upjohn, Pharmos, Rhône-Poulenc Rorer Inc (& Fisons), Roche Holding AG, Sandoz, Sanofi-Winthrop, Schering-Plough, Sequus Pharmaceuticals, Shire, SIBIA, Smith Kline plc, Sugen, Synaptic, Synthelabo, Titan, Warner Lambert, Xttrium, Xytex, Yamanouchi Pharmaceutical.

Available in two formats: CD-ROM or PRINTED

Price: $4,950.00

Please contact me to discuss this report

CD-ROM Format Print Format

Executive Briefing by Natalie S. Rudolph, Ph.D.

Publication date: January 2001

Number of pages: 170+ Pages, 25+ Exhibits, 20+ Companies Profiled

Everyone has heard the buzz and hype about the human genome sequence. What happens when the sequence is complete? Will the excitement end - or will it only begin? The completion of the human genome sequencing project has ushered in a "post-genomic" era in which the information and insights gleaned from raw gene sequences are being used for practical applications. These are likely to include:

Fundamental new ways to understand the molecular pathology of disease

Identification of genes associated with complex diseases for discovering new therapeutic targets

Validation of genetic markers for predicting the risk of disease susceptibility, differential diagnosis, and monitoring therapeutic progress

Use of genetic markers to select optimal drugs and doses for individual patients and reduce individual therapeutic experimentation

Examination of natural genetic variation between and within populations and its impact on health and disease

D&MD's Pharmacogenomics Executive Briefing cuts through the hype and far-off potential and explores the applications of pharmacogenomics that are likely to become useful sooner rather than later. These include:

Differential molecular diagnostics that lead to practical therapeutic alternatives, with a focus on cancer

Personalized medicine to improve drug efficacy and reduce adverse reactions

Consumer genomics coming to a Web site near you

Pharmacogenomics promises to expedite and facilitate the process of drug discovery, development and testing/approval, but this process will remain a long one in the post-genomic era. However, there are other fundamentally new and exciting ways in which pharmacogenomics can be used in research, in the clinic, and in the life sciences market. D&MD's Pharmacogenomics Executive Briefing covers these uses in-depth.

This Executive Briefing Features:

The relationship between the new field of pharmacogenomics and the established field of pharmacogenetics

Applications of pharmacogenomics in drug discovery, development, testing, and clinical medicine

Current business models in pharmacogenomics

Ways in which genetic information differs from medical information regarding privacy and confidentiality

Reasons why some of the world's largest pharmaceutical companies joined the SNP Consortium

Personalizing medicine by tailoring drug choices and doses to individual genotypes

E-genomics - using unique Internet capabilities for genomics

Consumer genomics - direct-to-consumer marketing of services and information

Profiles of 20+ leading companies focused on pharmacogenomics

Perspectives gleaned from interviews with more than 30 health and bioscience executives and experts

Company Profiles: AlphaGene, Celera Genomics, Clingenix, CuraGen, deCODE Genetics, diaDexus, DNA Sciences, Epigenomics GmbH, Framingham Genome, Medicine, Gemini Genomics plc, Genaissance Pharmaceuticals, Genome Therapeutics, Genomics Collaborative, GeneProfile AG, Genset SA, Incyte Pharmaceuticals, Millennium Pharmaceuticals, Myriad Genetics, Orchid BioSciences, PPD, PPGx, Sequenom, Variagenics.

Available in two formats: CD-ROM or PRINTED

Price: $1,995.00

Please contact me to discuss this report

CD-ROM Format Print Format

Executive Briefing by John Manfredonia, Ph.D.

Publication date: October 2000

Number of pages: 80+ Pages, 10+ Exhibits, 45+ Companies Profiled

These ascending technologies will lead to the next generation of biopharmaceutical and diagnostic discoveries.

We are in the early hours of the dawn of a new biological revolution with genuine depth and great diversity. Today's biotechnology industry is a colossal melting pot of many ascendant technologies, including molecular biology, pharmacogenomics, biotechnology tools, genomics, proteomics, bioinformatics, nanotechnology, telemedicine, electronics, fiber optics and computerization. This gelling of the industry offers new approaches to the discovery, design and production of drugs, vaccines, medical devices and diagnostics.

D&MD's Executive Briefing, A Time for Convergence in Biotechnology, provides a unique, comprehensive approach to the innovative developments in the industry by identifying the exponential metamorphosis of both the biotechnology and pharmaceutical industries. The evolution of these technologies will lead to the next generation of biopharmaceuticals.

A Time for Convergence in Biotechnology is essential for those in the pharmaceutical and biotechnology fields who are interested in the path these industries are taking as they reformulate themselves into the biopharmaceutical industry. This Briefing provides a qualitative understanding of the background of the biotechnology industry, predictions for its future beyond the completion of the mapping of the human genome and discussions of economic growth, making it a critical tool for anyone in or entering the industry.

Unique Benefits of the Briefing

Recent tables and charts reflecting new products and company Federal Drug Administration approvals, presenting important biotechnology related data.

In-depth company profiles in both developmental and narrow niches of the industry, identifying leading positions and strategy insights.

Cascade of the biotechnology industry outlining the direction of technological discovery and its value to the market.

Identification and review of challenges facing the industry and suggestions for global visions.

Analysis of thirty-three therapeutic market trends through 2003, highlighting areas of opportunity.

Available in two formats: CD-ROM or PRINTED

Price: $1,995.00

Please contact me to discuss this report

CD-ROM Format Print Format

Executive Briefing by Dr. Sreten Bogdanovic & Dr. Beata Langlands

Publication date: March 2001

Number of pages: 150+ Pages, 15+ Exhibits, 25+ Companies Profiles

In traditional medical practice therapeutic choices follow diagnosis, which may be based on clinical signs alone, or may be made in conjunction with an in vivo or in vitro diagnostic test. However, the effectiveness of the prescribed drug therapy and the likelihood of side effects often cannot be predicted for individual patients. Now a new generation of theranostic tests promises to transform the art of medical diagnosis and treatment into a predictive science. Theranostic tests are being developed specifically for predicting and assessing drug response rather than diagnosing disease.

One of the major current applications of theranostics is to select patients for treatments that are particularly likely to benefit them and unlikely to produce side-effects. Another major application is to provide an early and objective indication of treatment efficacy in individual patients, so that (if necessary) the treatment can be altered with a minimum of delay. D&MD's Theranostics Executive Briefing will detail these applications, as well as profile the leading companies developing theranostics products.

Theranostics aims at enhancing the effectiveness of drugs, and as such represents a commercial opportunity for both the pharmaceutical and diagnostic industries as illustrated by this Briefing. It is likely to lead to more pharmaceutical companies developing diagnostic divisions, or acquiring diagnostics companies. It also presents fresh opportunities for collaboration between diagnostic and pharmaceutical companies in bringing lucrative new drugs to market. Traditional diagnostic companies are operating in an industry that is currently growing at a rate of only 3-5% per annum overall, and need to seize new opportunities to ensure their survival. Overall, the advent of theranostics is expected significantly to increase healthcare spending on diagnostics.

Future progress in theranostics will draw on developments in pharmacogenomics, which seeks to establish correlations between responses to specific drugs and the genetic profiles of patients. Currently patient genetic data is used mainly to make drug development more efficient and cost-effective. D&MD's Briefing summarizes key developments in this technology area and profiles leading companies analyzing genetic variability, in particular SNP variability, and drug responses.

The potential market for theranostics is enormous, neither diagnostics nor pharmaceutical companies can afford to ignore this new trend. Order your copy of D&MD's Theranostics Briefing today!

Benefits of this Executive Briefing:

» In-depth history and explanation of theranostics and its potential to provide personalized medicine for both the diagnostic and pharmaceutical industries

» Learn where these new technologies are improving patient and clinical trials population selection, leading to improved clinical trials success and product effectiveness

» Coverage of therapeutic areas where theranostics has already made its mark and a review of the technology developments in these areas

» Coverage of proven personalized medicine approaches for using the